Liver Cirrhosis Network Cohort Study
NCT05740358, Active not recruiting, Northwestern University
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Liver Cirrhosis Network Cohort Study | ClinicalTrials.gov |
| NCT number | NCT05740358 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Enrollment | 1,222 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Northwestern University | ClinicalTrials.gov |
| Conditions | Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis | ClinicalTrials.gov |
| First posted | 2023-02-23 | ClinicalTrials.gov |
| Last updated | 2026-01-13 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Time-to-decompensation | 3 years | Time-to-decompensation, defined as any of the following events: * Ascites: definite as determined by adjudication * Hepatic Encephalopathy (HE): definite or highly likely as determined by adjudication * Portal hypertensive upper gastrointestinal (GI) bleeding: definite as determined by adjudication | ClinicalTrials.gov |
| Secondary | Number of decompensations | 3 years | Number of decompensations (treated as a count variable in analyses) | ClinicalTrials.gov |
| Secondary | All-cause mortality | 3 years | All-cause mortality (treated as time-to-event in analyses) | ClinicalTrials.gov |
| Secondary | Adjudicated liver-related mortality | 3 years | Adjudicated liver-related mortality (treated as time-to-event in analyses) | ClinicalTrials.gov |
| Secondary | All-cause hospitalizations | 3 years | All-cause hospitalizations (treated as a count variable in analyses) | ClinicalTrials.gov |
| Secondary | Number of liver-related hospitalizations | 3 years | Liver-related hospitalizations (treated as a count variable in analyses) | ClinicalTrials.gov |
| Secondary | Time to liver transplantation | 3 years | Liver transplantation (treated as time-to-event in analyses) | ClinicalTrials.gov |
| Secondary | Time to development of hepatocellular carcinoma (HCC) | 3 years | Development of HCC (treated as time-to-event in analyses) | ClinicalTrials.gov |
| Secondary | Time to development of portal and/or mesenteric vein thrombosis | 3 years | Development of portal and/or mesenteric vein thrombosis (treated as time-to-event in analyses) | ClinicalTrials.gov |
| Secondary | Change in liver stiffness as measured by vibration-controlled transient elastography (VCTE) | 3 years | Liver stiffness as measured by VCTE (treated as continuous measure in analyses) | ClinicalTrials.gov |
| Secondary | Degree of fibrosis as measured by fibrosis-4 index (FIB-4) | 3 years | Degree of fibrosis as measured by FIB-4 (treated as continuous measure in analyses) | ClinicalTrials.gov |
| Secondary | Overall physical health and overall mental health as measured by Patient Reported Outcomes Measurement Information System (PROMIS-29+2 profile v2.1) | 3 years | Overall physical health and overall mental health as measured by Patient Reported Outcomes Measurement Information System (PROMIS-29+2 profile v2.1) relevant "T-scores," a continuous measure. T-scores are normalized to the population and are centered at 50 with anticipated standard deviation of 10. A higher score means better "health." | ClinicalTrials.gov |
| Secondary | Change in cognitive function as measured by Stroop Test | 3 years | Change in cognitive function as measured by Stroop Test (treated as continuous measure in analyses). Measured as time to complete the test. A higher score means longer time to complete, which means more impaired function. Minimum score is 0, and there is no maximum score. | ClinicalTrials.gov |
| Secondary | Change in frailty as measured by the Liver Frailty Index | 3 years | Change in frailty as measured by the Liver Frailty Index (treated as continuous measure in analyses). A higher score means the participant is more frail. The score is based on grip strength, number of chair stands per second, and balance time. https://liverfrailtyindex.ucsf.edu/ Maximum score of 6, and there is no minimum score. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 39018024 | DERIVED | PubMed |
Grants 11
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U01DK130113 | Statin Therapy for patients with compensated Cirrhosis | TAPPER, ELLIOT; PARIKH, NEEHAR DILIP | UNIVERSITY OF MICHIGAN AT ANN ARBOR | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130134 | Liver Cirrhosis Network: Clinical Research Centers | SANYAL, ARUN J; BAJAJ, JASMOHAN S | VIRGINIA COMMONWEALTH UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130168 | Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies | KHALILI, MANDANA; HAMEED, BILAL | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130177 | Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis | MOYLAN, CYNTHIA A; KAPPUS, MATTHEW R. | DUKE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130180 | Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy | DASARATHY, SRINIVASAN | CLEVELAND CLINIC LERNER COM-CWRU | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130181 | Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic | SHAH, VIJAY H.; SIMONETTO, DOUGLAS A. | MAYO CLINIC ROCHESTER | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130185 | Evaluating risk factors for cirrhosis progression and response to statin therapy among a cohort of patients with cirrhosis | GOLDBERG, DAVID SETH | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130190 | San Diego Cirrhosis Clinical Research Network | LOOMBA, ROHIT | UNIVERSITY OF CALIFORNIA, SAN DIEGO | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130197 | USC Cirrhosis Clinical Center | TERRAULT, NORAH A. | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U01DK130221 | Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network | BROWN, ROBERT S; VERNA, ELIZABETH CLARICE | WEILL MEDICAL COLL OF CORNELL UNIV | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
| U24DK130164 | Liver Cirrhosis Network: Scientific and Data Coordination Center | SMITH, ABIGAIL; BONNER, LAUREN BALMERT; LADNER, DANIELA P | NORTHWESTERN UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)